research papers

Recruitment and Active Studies

The Lakeside Healthcare Research and Innovation Unit has been set up to provide all our patients with the opportunity to take part in clinical research studies which are relevant to them.

Recruitment

GSK VIGILANT

A multicentre, randomised, double-blind, parallel-group, placebo-controlled study of the efficacy and safety of early depemokimab initiation as an add-on treatment in COPD patients with Type

To find out more, including the possible risks and benefits of being in this study, please contact us.

GSK ENDURA

A randomised, double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of depemokimab in adult participants with COPD with Type 2 inflammation.

To find out more, including the possible risks and benefits of being in this study, please contact us.

MOVe-NOW clinical study

This study will be testing an investigational medicine for COVID-19.

Investigators want to see how well it may work and if it is safe in adults with COVID-19 who are more likely to have serious symptoms from COVID-19.

You may be able to take part in this study if you are 18 years or older and:

  • have a health condition that may make you more likely to become very sick from COVID-19
  • are not in hospital for any reason

There are more requirements, which the study doctor will discuss with you. You do not need to currently have COVID-19 to consider taking part in this study.

If you test positive for COVID-19, you will:

  • be in the study for about 6 months
  • visit the study clinic about 7 times
  • have about 3 virtual (video or phone) visits with the study team

There is no cost to take part in this study. Reimbursement may be available for your study-related travel expenses.

To find out more, including the possible risks and benefits of being in this study, please contact us.

Zenith Study

A Phase 3 global, randomized, double-blind, placebo-controlled study

To evaluate the efficacy and safety of Zilebesiran in addition to standard of care in reducing major adverse cardiovascular events in adult patients with hypertension not adequately controlled and with either established cardiovascular disease or high risk for cardiovascular disease

To find out more, including the possible risks and benefits of being in this study, please contact us.

Beethoven Study

A phase 3, placebo-controlled, double-blinded, randomized study to evaluate the efficacy, safety, and tolerability of a Clostridioides difficile vaccine in adults 65 years of age and older

To find out more, including the possible risks and benefits of being in this study, please contact us.

Current Studies

Lakeside Healthcare Research and Innovation Unit

  • Moderna Nova - A Phase 3, randomized, observer-blinded, placebo-controlled study to evaluate the safety and efficacy of mRNA-1403, a multivalent candidate vaccine to prevent norovirus acute gastroenteritis in adults aged ≥18 years
  • MSD MK00616-015 - A Phase 3, randomised, placebo-controlled clinical study to evaluate the efficacy and safety of MK-0616 in reducing major adverse cardiovascular events in participants at high cardiovascular risk.
  • Novartis Victorion - 1 Prevent - A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients.
  • AstraZeneca Tharros - This trial will see if an investigational vaccine can protect people 60 years of age or older against symptoms caused by the norovirus stomach bug.
  • GSK RoCCPORT - A prospective cohort study of patients with refractory or unexplained chronic cough measuring cough variability and burden on patients’ lives.
  • Clinical Trial for an Investigational Bird Flu Vaccine - Moderna is looking for individuals 18 years of age or older to take part in a clinical trial of an investigational vaccine for the pandemic bird flu, H5N1, a form of influenza A.
  • MSD MK-0616-037 - A Phase 3, multicentre, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of Enlicitide Decanoate coadministered with Rosuvastatin in adults with hyperlipidaemia.